Philippe A Cassier

Summary

Publications

  1. ncbi request reprint Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience
    Philippe A Cassier
    Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
    Cancer 115:3392-9. 2009
  2. ncbi request reprint Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma
    Philippe A Cassier
    Department of Medical Oncology, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Eur J Gastroenterol Hepatol 22:1111-7. 2010
  3. ncbi request reprint Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database
    P A Cassier
    Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, Sutton The Institute of Cancer Research, Sutton, UK Departments of Medical Oncology
    Ann Oncol 25:1222-8. 2014
  4. pmc New developments in treatment of ovarian carcinoma: focus on trabectedin
    Philippe A Cassier
    Departement de Medecine
    Cancer Manag Res 2:233-42. 2010
  5. pmc A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
    P A Cassier
    Department of Medicine, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 109:909-14. 2013
  6. ncbi request reprint Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era
    Philippe A Cassier
    Department of Medicine, Centre Leon Berard, Lyon, France
    Clin Cancer Res 18:4458-64. 2012
  7. doi request reprint Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
    Philippe A Cassier
    Department of Medicine, Leon Berard Center, Lyon, France
    Cancer 118:1649-55. 2012
  8. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
  9. doi request reprint Therapeutic pipeline for soft-tissue sarcoma
    Philippe A Cassier
    Departement de Medecine, Centre Leon Berard, 69008 Lyon, France
    Expert Opin Pharmacother 12:2479-91. 2011
  10. ncbi request reprint Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib
    Philippe A Cassier
    Conticanet Network of Excellence LSH 060188, Département de Médicine, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Curr Gastroenterol Rep 10:555-61. 2008

Detail Information

Publications28

  1. ncbi request reprint Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience
    Philippe A Cassier
    Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
    Cancer 115:3392-9. 2009
    ..The authors assessed the efficacy of gemcitabine-oxaliplatin combination (GEMOX) in the treatment of patients with metastatic neuroendocrine tumors...
  2. ncbi request reprint Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma
    Philippe A Cassier
    Department of Medical Oncology, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Eur J Gastroenterol Hepatol 22:1111-7. 2010
    ..Currently, there is no standard chemotherapy for this disease, but several single agents and combinations have shown promising activity, most notably gemcitabine-based combinations...
  3. ncbi request reprint Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database
    P A Cassier
    Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, Sutton The Institute of Cancer Research, Sutton, UK Departments of Medical Oncology
    Ann Oncol 25:1222-8. 2014
    ..In addition, we analysed efficacy and toxicity regarding the sarcoma population enrolled in phase I trials...
  4. pmc New developments in treatment of ovarian carcinoma: focus on trabectedin
    Philippe A Cassier
    Departement de Medecine
    Cancer Manag Res 2:233-42. 2010
    ..Current research focuses on the identification of predictive factors for patients treated with trabectedin, as well as the development of other combinations...
  5. pmc A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
    P A Cassier
    Department of Medicine, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 109:909-14. 2013
    ..Soft tissue sarcomas (STS) are rare tumours for which treatment options are limited in the advanced setting. Histone deacetylase inhibitors have shown activity in preclinical models of STS...
  6. ncbi request reprint Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era
    Philippe A Cassier
    Department of Medicine, Centre Leon Berard, Lyon, France
    Clin Cancer Res 18:4458-64. 2012
    ..Platelet-derived growth factor receptor-alpha (PDGFRA) mutations are found in approximately 5% to 7% of advanced gastrointestinal stromal tumors (GIST). We sought to extensively assess the activity of imatinib in this subgroup...
  7. doi request reprint Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
    Philippe A Cassier
    Department of Medicine, Leon Berard Center, Lyon, France
    Cancer 118:1649-55. 2012
    ..CSF1 is expressed by a minority of tumor cells, which, in turn attract non-neoplastic inflammatory cells that express CSF1 receptor (CSF1R) through a paracrine effect...
  8. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
    ..Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer...
  9. doi request reprint Therapeutic pipeline for soft-tissue sarcoma
    Philippe A Cassier
    Departement de Medecine, Centre Leon Berard, 69008 Lyon, France
    Expert Opin Pharmacother 12:2479-91. 2011
    ..After the initial success of imatinib in gastrointestinal stromal tumors, several other compounds have shown promising activity in some but not all subgroups of sarcoma...
  10. ncbi request reprint Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib
    Philippe A Cassier
    Conticanet Network of Excellence LSH 060188, Département de Médicine, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Curr Gastroenterol Rep 10:555-61. 2008
    ..This article reviews the current knowledge regarding IM and SU resistance in GIST, as well as the available options for the management of GIST resistant to IM and SU...
  11. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
    ..We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial...
  12. doi request reprint [Targeted therapy of sarcomas]
    Philippe A Cassier
    Hopital Edouard Herriot, Service d Oncologie Medicale, Lyon, France
    Bull Cancer 95:963-74. 2008
    ..Together with the current development of numerous targeted therapies, these recent progress are the basis of tomorrow's personalised medicine for patients with soft tissue sarcoma...
  13. doi request reprint Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors
    Thomas Walter
    Hospices Civils de Lyon, Hopital Edouard Herriot, Fédération des spécialités digestives, Lyon, France
    Clin Colorectal Cancer 9:248-54. 2010
    ..The aim of this study was to retrospectively analyze the efficacy and safety of the combination of 5-fluorouracil (5-FU), dacarbazine, and epirubicin (FDE) in 39 patients with advanced, well-differentiated neuroendocrine tumors (NETs)...
  14. ncbi request reprint A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
    Philippe A Cassier
    Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Lyon, France
    Cancer 113:2532-8. 2008
    ..A study was conducted to determine the efficacy, tolerability, and safety of concurrent cisplatin and vinorelbine chemotherapy and radiotherapy in patients with previously untreated brain metastases from breast cancer...
  15. doi request reprint Imatinib mesilate for the treatment of gastrointestinal stromal tumour
    Philippe A Cassier
    unité de jour d oncologie médicale multidisciplinaire, Pavillon E, Hopital Edouard Herriot, 5 Place d Arsonval, 69003, Lyon, France
    Expert Opin Pharmacother 9:1211-22. 2008
    ..Imatinib mesilate, which was approved in 2002 for the treatment of patients with advanced GIST, has dramatically changed the course of the disease...
  16. ncbi request reprint Molecular response prediction in gastrointestinal stromal tumors
    Philippe A Cassier
    Departement de Medecine, Centre Leon Berard, Lyon, France
    Target Oncol 5:29-37. 2010
    ..Here, we review the current data regarding molecular prediction of response in this disease...
  17. ncbi request reprint Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes
    Jean Yves Blay
    Department of Medicine, Centre Leon Berard, Lyon 69008, France
    Discov Med 13:357-67. 2012
    ..For this aspect also, GIST is again a paradigmatic model for oncology, as many tumors with a higher prevalence will be fragmented in different molecular subsets and are going to become rare disease in the years to come...
  18. ncbi request reprint Emerging drugs for the treatment of soft tissue sarcomas
    Philippe A Cassier
    Unité de Jour Oncologie Médicale Multidisciplinaire, Hopital Edouard Herriot, Lyon, France
    Expert Opin Emerg Drugs 12:139-53. 2007
    ..This review summarises treatment strategies in the context of advanced disease and discusses new compounds being developed for patients with soft tissue sarcomas...
  19. doi request reprint Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?
    Jean Yves Blay
    Département de Médecine and Unité INSERM U590, Centre Leon Berard, Lyon, France
    Curr Opin Oncol 21:360-6. 2009
    ..In this setting, the optimal duration of treatment is not known, and it is generally considered that treatment should be given until progression or intolerance...
  20. pmc Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
    Alice Levard
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008, Lyon, France
    BMC Cancer 13:109. 2013
    ..Data on the management of patients with advanced SFT is scarce: chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be more efficient...
  21. pmc Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death
    Andrea Paradisi
    Apoptosis, Cancer and Development Laboratory Equipe labellisée La Ligue, LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052 CNRS UMR5286, Universite de Lyon, Centre Leon Berard, Lyon, France
    EMBO Mol Med 5:1821-34. 2013
    ..Together these data suggest that combining conventional chemotherapies with netrin-1 interference could be a promising therapeutic approach. ..
  22. ncbi request reprint Imatinib mesylate for the treatment of gastrointestinal stromal tumor
    Philippe A Cassier
    Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 10:623-34. 2010
    ..Recently, IM was approved for the postoperative treatment of patients with completely resected localized GIST...
  23. ncbi request reprint A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Philippe A Cassier
    Medical Oncology, Hopital Edouard Herriot, Université de Lyon et Hospices Civils de Lyon, Lyon, France
    Breast Cancer Res Treat 109:343-50. 2008
    ..In first-line metastatic breast cancer, both paclitaxel (P)-doxorubicin (A) and docetaxel (D)-doxorubicin (A) combinations have shown superiority over treatments without taxane. The aim of this study was to compare the two combinations...
  24. doi request reprint Trabectedin for the management of soft-tissue sarcoma
    Laurence Boudou
    unité de jour d oncologie médicale multidisciplinaire, Hopital Edouard Herriot, Lyon, France
    Expert Rev Anticancer Ther 9:727-37. 2009
    ..Current research focuses on the identification of predictive factors for patients treated with trabectedin as well as the development of other combinations...
  25. ncbi request reprint Emerging therapies for soft-tissue sarcomas
    Alice Levard
    Department of Medical Oncology, Leon Berard Cancer Center, 28 rue Laennec, Lyon 69008, France
    Hematol Oncol Clin North Am 27:1063-78. 2013
    ..This article reviews recent clinical data on emerging therapies for soft-tissue sarcoma. ..
  26. doi request reprint Gastrointestinal stromal tumors of the stomach and duodenum
    Philippe A Cassier
    Departement de Medecine, Centre Leon Berard, Lyon, France
    Curr Opin Gastroenterol 27:571-5. 2011
    ..New data regarding the adjuvant treatment of these tumors were recently reported and are likely to impact patient management...
  27. ncbi request reprint Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases
    Philippe A Cassier
    unité de jour d oncologie médicale multidisciplinaire, Hopital Edouard Herriot, Lyon, France
    Eur J Endocrinol 158:935-8. 2008
    ..Mifepristone clearly improved skin lesions and diabetes associated with hypercorticism. The beneficial effect lasted for about 10 months. In both cases, recurrent hypertension and hypokalemia eventually required adrenalectomy...
  28. ncbi request reprint Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress
    Victor Moreno García
    Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Discov 1:207-12. 2011
    ..We therefore propose a more efficient parallel predictive biomarker and clinical anticancer drug development process to deal with the obstacles hindering progress...